Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depression
Official title: Relationship Between Response to Transcranial Magnetic Stimulation and Peripheral Inflammatory and Neuroprotective Biomarkers in Patients With Treatment-Resistant Depression
Run by Gulhane Training and Research Hospital · NCT07673913 · Data updated 2026-11-12
This study tests whether a four-week course of intermittent theta burst stimulation can help people with treatment-resistant depression by looking at symptoms, thinking skills, and blood biomarkers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Gulhane Training and Research Hospital Government |
| Locations | 2 sites (Ankara, Ankara and 1 other locations) |
| Status | Recruiting |
| Started | September 1, 2026 |
| Main results expected | September 1, 2027 |
| Study ends | September 1, 2027 |
| Registry record updated | September 14, 2026 |
| Trial ID | NCT07673913 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18-55 with a DSM-5-TR diagnosis of major depressive disorder who have failed at least two adequate antidepressant trials.
✕Probably not a fit
Individuals unable to complete the iTBS protocol or without a biological response profile may not experience meaningful benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-center study enrolling 50 adults with treatment-resistant depression and 50 healthy controls. Participants with TRD receive active iTBS to the left dorsolateral prefrontal cortex over 20 sessions in four weeks, while controls provide baseline comparisons. The research will assess clinical symptoms, executive function, and peripheral inflammatory and neuroprotective biomarkers to explore mechanisms of response. The trial aims to identify potential biomarkers that correlate with treatment outcomes and to deepen understanding of how iTBS affects neurobiology in TRD. The study is investigator-initiated and conducted at Gulhane Training and Research Hospital in Ankara, Turkey.
Why it matters
Potential benefit: If successful, patients with TRD could experience improved depressive symptoms and functional outcomes from iTBS, possibly enabling more personalized treatment strategies.
How similar studies have gone: Previous neuromodulation studies suggest iTBS can alleviate depressive symptoms, but biomarker-guided prediction remains an emerging area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria Treatment-Resistant Depression Group: Age between 18 and 55 years. Male or female participants. Diagnosis of Major Depressive Disorder according to DSM-5-TR criteria. Inadequate response to at least two antidepressant treatments administered at adequate doses and durations. Eligible for transcranial magnetic stimulation (TMS) treatment. Able and willing to provide written informed consent. Able to complete neuropsychological assessments. Able to attend study visits and complete the treatment protocol. Healthy Control Group: Age between 18 and 55 years. Male or female participants. No current DSM-5-TR psychiatric disorder. Able and willing to provide written informed consent. Able to complete neuropsychological assessments. Exclusion Criteria Schizophrenia, bipolar disorder, organic mental disorders, or other major psychiatric disorders. History of epilepsy, brain tumor, severe head trauma, or significant neurological disease. Any contraindication to TMS. Presence of intracranial metal implants, cardiac pacemakers, cochlear implants, or other incompatible implanted devices. Active infection. Autoimmune disease or chronic inflammatory disease. Electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation within the previous 5 years. Previous intravenous or intranasal ketamine treatment. Pregnancy or breastfeeding. Active alcohol or substance use disorder. Inability to comply with study procedures. Inability to tolerate the iTBS protocol. Withdrawal of informed consent at any stage of the study.
Where it's running
-
Gulhane Training and Research Hospital
Ankara, Turkey (Türkiye) Recruiting -
Gulhane Training and Research Hospital
Ankara, Ankara, Turkey (Türkiye) Not yet recruiting
Study contacts
- Study coordinator: BEYAZIT GARİP, Principal Investigator
- Email: beyazitgarip@gmail.com
- Phone: +903123044512
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can tACS modulate motivation and reward signals in cannabis use disorder and depression
We’re testing whether a gentle brain stimulation method (tACS) can boost motivation and reward responses in adults with cannabis use and/or depression to see if it helps with anhedonia.
-
Neural links for real-world emotions in mood and anxiety
Researchers are testing how real-life emotional moments relate to brain activity and stress responses in young adults with mood and anxiety symptoms, using smartphones, self-reports, tasks, and MRI.
-
French Minds: a French, Multimodal Cohort Study of Severe Psychiatric Disorders and Healthy Controls
This study tests whether people with mood, psychotic, or autism disorders can be grouped into more similar subtypes based on social withdrawal and anhedonia, across ages 15 to 60.
-
EEG-Guided TMS for Adults With Depression
This study tests whether delivering intermittent theta burst stimulation (iTBS) timed to brain waves using EEG can improve treatment for adults with major depressive disorder who have not responded to usual antidepressants.
-
DHEA add-on to standard antidepressants for treatment-resistant depression
This trial tests whether adding 100 mg/day of DHEA to patients’ current antidepressant treatment helps people with treatment-resistant depression feel better.
-
iTBS to help anhedonia in depression (dual left DLPFC + OFC or left DLPFC alone)
A brain stimulation study tests whether intermittent theta burst stimulation can help people with major depression who have anhedonia, using both dual-target (left DLPFC and OFC) and single-target (left DLPFC) approaches.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.